L-glutamine conjugate of meselamine: A novel approach for targeted delivery to colon

Journal of Drug Delivery Science and Technology

Volumn 19, Issue 1, 2009, Pages 67-72

  Dhaneshwar, Suneela S ^a   Kandpal, M ^a   Vadnerkar, G ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Inflammatory bowel disease; L glutamine; Meselamine

Indexed keywords

GLUTAMINE; MESALAZINE; MYELOPEROXIDASE; SALAZOSULFAPYRIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLITIS; COLON FLORA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG STABILITY; DRUG TARGETING; ENTERITIS; ENZYME ACTIVITY; EXPERIMENTAL ANIMAL; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; MALE; NONHUMAN; PH; QUANTITATIVE ANALYSIS; RAT; SOLVENT EFFECT;

EID: 59849086408     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(09)50009-3     Document Type: Article

References (39)

1. Meyers S., Sachar D.B. - Medical therapy of Crohn's disease. - In: Inflammatory Bowel Disease, J.B. Kersnar, R.G. Shorter Ed., Williams and Wilkins, Baltimore, 1995, pp. 695-714.
2. Wallace et al. - Derivatives of 4- or 5-aminosalicylic acid. - US Patent US 2006/0270635 A1, 30 Nov. 2006.
3. Jung Y.N., Lee J.S., Kim Y.M. - Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as acolon specific prodrug of 5-aminosalicylic acid. - J. Pharm Sci., 89 (5), 594-601, 2000.
4. Oz H.S., Ebersole J.L. - Application of prodrugs to inflammatory diseases of the gut. - Molecules, 13, 452-474, 2008.
5. Chourasia M.K., Jain S.K. - Pharmaceutical approaches to colon targeted drug delivery systems. - J. Pharm. Sci., 6, 33-66, 2003.
6. Milojevic S., Newton J.M., Cummings J.H., Gibson G.R., Botham R.L., Ring S.G., Stockham M., Allwood M.C. - Amylose as a coating for drug delivery to the colon: Preparation and in vitro evaluation using glucose pellets. - J. Control Release, 38, 85-94, 1996.
7. Van der Mooter G., Maris B., Samyn C., Augustijns P., Kinget R. - Use of azo polymers for colon-specific drug delivery. - J. Pharm. Sci., 86, 1321-1327, 1997.
8. Khan M.Z., Stedul H.P., Kurjakovic N. - A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit L100 and Eudragit S100 combinations. - Drug Dev. Ind. Pharm., 26, 549-554, 2000.
9. Wilding I.R., Hardy J.G., Sparrow R.A., Davis S.S., Daly P.B., English J.R. - In vivo evaluation of enteric-coated naproxen tablets using gamma scintigraphy. - Pharm Res., 9, 1436-1441, 1992.
10. Fukui E., Miyamura N., Uemura K., Kobayashi M. - Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. - Int. J. Pharm., 204, 7-15, 2000.
11. Gupta V.K., Beckert T.E., Price J.C. - A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development. - Int. J. Pharm., 213, 83-91, 2001.
12. Siew L.F., Man S.M., Newton J.M., Basit A.W. - Amylose formulations for drug delivery to the colon: a comparison of two fermentation models to assess colonic targeting performance in vitro. - Int. J. Pharm., 273, 129-134, 2004.
13. Zambito Y, Di Colo G. - Preparation and in vitro evaluation of chitosan matrices for colonic controlled drug delivery. - J. Pharm. Pharm. Sci., 6, 274-281, 2003.
14. Riley S.A., Turnberg L.A. - Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowel disease. - Q. J. Med., 75, 551-562, 1990.
15. Sutherland L.R., May G.R., Shaffer E.A. - Sulfasalazine revisited; a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. - Ann. Intern. Med., 118, 540-549, 1993.
16. Sutherland L.R., Rothy D.E., Beck P.L. - Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. - Inflammatory Bowel Disease, 3, 65-78, 1997.
17. Mahmud N., Kamm M.A., Dupas J.L. - Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomized, multicentre study. - Gut, 49, 552-556, 2001.
18. Rao S.S.C., Read N.W., Holdsworth C.D. - Influence of olsalazine on gastrointestinal transit in ulcerative colitis. - Gut, 28, 1474-1477, 1987.
19. Lacey J.M., Wilmore D.W. - Is glutamine a conditionally essential amino acid? - Nutr. Rev., 48, 297-309, 1990.
20. www.anyvitamins.com
21. Bozzetti F., Biganzoli L., Gavazzi C. - Glutamine supplementation in cancer patients receiving chemotherapy: A double-blind randomized study. - Nutrition, 13, 748-751, 1997.
22. Dhaneshwar S., Chaturvedi S.C. - Synthesis and biological evaluation of ketoprofen glycinate methyl ester: a prodrug concept. - Indian Drugs, 31, 374-377, 1994.
23. Furniss B.S., Hannaford A.J., Smith P.W.G., Tatchell A.R. - Aromatic compounds. - Vogel's Textbook Of Practical Organic Chemistry, The English Language Bookman, London, 2004, pp. 835-836.
24. March J. - Aliphatic electrophillic substitution. - In: Advanced Organic Chemistry, Reactions, Mechanisms and Structure, Wiley Eastern Ltd., Singapore, 1992, pp. 635-636.
25. Indian Pharmacopoeia- Reagents and solutions. - The Controller of Publications, New-Delhi, 1996, Vol. II, pp. A 144-145.
26. Nielsen N.M., Bundgaard H. - Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. - J. Pharm. Sci., 77 (4), 285-298, 1988.
27. Uekama K., Minami K., Hirayama F. - 6A-O-[(4-biphenylyl) acetyl]-alpha-, -beta-, and -gamma-cyclodextrins and 6A-deoxy-6A- (4-biphenylyl) acetyl] amino]-alpha-, -beta-, and -gamma-cyclodextrins: potential prodrugs for colon-specific delivery. - J. Med. Chem., 40, 2755-2561, 1997.
28. Yamada T., Marshall S., Specian R.D., Grisham M.B. - A comparative analysis of two models of colitis in rats. - Gastroenterology, 102 (5), 1524-1534, 1992.
29. Hartmann G., Bidlingamaier C., Seigmund B., Albrich S., Schulze J., Tschoep K.A., Eigler H.A., Lehr S. - Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. - Endres. J Pharmacol. Exp.Ther., 292 (1), 22-30, 2000.
30. Krawisz J.E., Sharon P., Stenson W.F. - Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. - Gastroenterology, 87, 1344-1350, 1984.
31. Vogel G.H., Vogel W.H. - Drug Discovery and Evaluation-Pharmacological Assays. Berlin: Springer-Verlag, 1997, pp. 445-447.
32. Rainsford K.D., Whitehouse M.W. -Anti-inflammatory/anti-pyretic salicylic acid esterswith low gastric ulcerogenic activity. - Inflammation Res., 10 (5), 451-456, 1980.
33. Rainsford K.D. - A synergistic interaction between aspirin, or other non-steroidal anti-inflammatory drugs, and stress which produces severe gastric mucosal damage in rats and pigs. - Agents Actions, 5, 553-558, 1975.
34. Cioli V., Putzolu S., Rotzolu S., Rossi V., Barcellona P.S., Corradino C. - The role of direct tissue contact in the production of gastrointestinal ulcers by anti-inflammatory drugs in rats. - Toxicol. Appl. Pharmacol., 50, 283-289, 1979.
35. Riley S.A. - What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? - Gut, 42, 761-763, 1998.
36. Pullar T., Hunter J.A., Capell H.A. - Which component of sulphasalazine is active in rheumatoid arthritis? - Br. Med. J. Clin. Res., 290, 1535-1538, 1985.
37. Taggart A.J., Neumann V.C., Hill J., Astbury C., Le Gallez P., Dixon J.S. - Which is the active moiety of sulphasalazine in rheumatoid arthritis 5-ASA or sulphapyridine? - Drugs, 31, 27-34, 1986.
38. Neumann V.C., Taggart A.J., Le Gallez P., Astbury C., Hill J., Bird H.A. - A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. - J. Rheumatol., 13, 285-297, 1986.
39. Bird H.A. - Sulphasalazine, sulphapyridine or 5-aminosalicylic acid - Which is the active moiety in rheumatoid arthritis? - Br. J. Rheumatol., 34 (2), 16-19, 1995.